ENZN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ENZN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Enzon Pharmaceuticals's Operating Income for the three months ended in Dec. 2023 was $-0.22 Mil. Enzon Pharmaceuticals's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. Enzon Pharmaceuticals has no debt. The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Enzon Pharmaceuticals Inc has no debt.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Enzon Pharmaceuticals's Interest Coverage or its related term are showing as below:
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Enzon Pharmaceuticals's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Enzon Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Interest Coverage | Get a 7-Day Free Trial | No Debt | No Debt | No Debt | No Debt | No Debt |
Enzon Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Interest Coverage | Get a 7-Day Free Trial | No Debt | No Debt | No Debt | No Debt | No Debt |
For the Biotechnology subindustry, Enzon Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Enzon Pharmaceuticals's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Enzon Pharmaceuticals's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
If Interest Expense is negative and Operating Income is positive, then
Interest Coverage | = | -1 | * | Operating Income | / | Interest Expense |
Else if Interest Expense is negative and Operating Income is negative, then
The company did not have earnings to cover the interest expense. |
Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then
The company had no debt (1). |
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Enzon Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as
Here, for the fiscal year that ended in Dec. 2023, Enzon Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-1.04 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Enzon Pharmaceuticals had no debt (1). |
Enzon Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
Here, for the three months ended in Dec. 2023, Enzon Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-0.22 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Enzon Pharmaceuticals had no debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's Financial Strength is.
Enzon Pharmaceuticals (OTCPK:ENZN) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Thank you for viewing the detailed overview of Enzon Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Randolph C Read | director | C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022 |
Jaffrey Adam Firestone | director | C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479 |
Family Fund Couchman | other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Jordan Bleznick | director | C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016 |
Pearce Michael Cooper | other: See explanation of responses | 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517 |
Harper Asset Management Llc | other: See explanation of responses | 2945 S CENTER GREEN CT, G215, BOULDER CO 80301 |
Brian James Harper | other: See explanation of responses | 6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301 |
Myrexis, Inc. | other: See Footnote 1 | 600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020 |
Xstelos Corp. | other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Jonathan Couchman | 10 percent owner, other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Carl C Icahn | 10 percent owner | C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160 |
Richard L Feinstein | officer: VP-Finance and PFO | |
Jonathan Christodoro | director | C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160 |
Kostas D Odysseas | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Jennifer Isacoff Mcnealey | director | C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121 |
From GuruFocus
By Sydnee Gatewood Sydnee Gatewood • 12-02-2016
By Marketwired Marketwired • 09-03-2020
By Sheila Dang Sheila Dang • 06-23-2015
By Marketwired Marketwired • 01-04-2021
By gurufocus 10qk • 05-10-2010
By gurufocus 10qk • 08-09-2010
By gurufocus 10qk • 03-16-2011
By GuruFocus Research GuruFocus Editor • 06-22-2010
By gurufocus Todd Sullivan • 03-14-2008
By guruek guruek • 11-15-2009
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.